Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -67.65% | -53.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -67.65% | -53.81% | |||
| Cost of Revenue | -63.22% | -74.12% | |||
| Gross Profit | -71.92% | 89.72% | |||
| SG&A Expenses | 6.80% | -15.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.60% | 0.17% | |||
| Operating Income | 37.81% | -52.72% | |||
| Income Before Tax | -21.70% | 20.33% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -21.70% | 20.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.70% | 20.85% | |||
| EBIT | 37.81% | -52.72% | |||
| EBITDA | 23.54% | -36.88% | |||
| EPS Basic | -17.71% | 21.15% | |||
| Normalized Basic EPS | 35.93% | -46.76% | |||
| EPS Diluted | -17.71% | 21.84% | |||
| Normalized Diluted EPS | 35.93% | -46.76% | |||
| Average Basic Shares Outstanding | 3.38% | 0.42% | |||
| Average Diluted Shares Outstanding | 3.38% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||